



Attorney Docket No.: 5655.204-US

07P-1627
RECEIVED
SEP 24 2001
TECH CENTER
PATENT
1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Pedersen et al.

Confirmation No: 7651

Serial No.: 09/390,851

Group Art Unit: 1627

Filed: September 7, 1999

Examiner: Prasthoffer, T.

For: Enzyme Activity Screen With Direct Substrate Reloading

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box: Restrict
Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Preliminary Amendment and Response to Restriction Requirement


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box: Restrict
Commissioner for Patents
Washington, DC 20231

on September 17, 2001.

Kelley O'Patry
(name of person mailing paper)


(signature of person mailing paper)



Attorney Docket No.: 5655.204-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Pedersen et al.

Confirmation No: 7651

Serial No.: 09/390,851

Group Art Unit: 1627

Filed: September 7, 1999

Examiner: Prasthoffer, T.

For: Enzyme Activity Screen With Direct Substrate Reloading

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed July 19, 2001.

It is respectfully requested that the time for response to the Office Action dated July 19, 2001 be extended for a period of 1 month from August 19, 2001 to September 19, 2001. The required fee for the extension is estimated to be \$110.00.

The fee for claims has been calculated as shown below:

Total: $28 - 27 = 1 \times 18 = \18

Independent: $1 - 3 = 0 \times 80 = \$0$

Total additional fee for claims required is \$18.

Please charge the required extension and claims fees, estimated to be \$128, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

Date: September 17, 2001

09/21/2001 MWOLDER1 00000086 501701 09390851

01 FC:115 110.00 CH

09/21/2001 MWOLDER1 00000086 501701 09390851

02 FC:103 18.00 CH

RECEIVED
SEP 24 2001
PATENT
TECHNICAL CENTER 1600/2900

#15
M. G. J.
9/26/01